Moderna Also Shows "Over 90% Effectiveness 6 Months After Second Dose"

[Image source=Yonhap News]

[Asia Economy Reporter Cho Hyun-ui] Following Pfizer, Moderna's COVID-19 vaccine also maintained a prevention effectiveness of over 90% six months after the second dose.

On the 13th (local time), CNBC reported that Moderna released preliminary results from its Phase 3 clinical trial update.

According to the company, Moderna's vaccine showed over 90% effectiveness in preventing COVID-19 six months after the second dose. It demonstrated more than 95% effectiveness in preventing severe COVID-19 even six months after vaccination.

This Phase 3 trial update analyzed cases of about 900 confirmed COVID-19 patients occurring up to the 9th. Among them, over 100 were severe cases.

Based on clinical trial results showing prevention effectiveness lasting more than six months, Moderna is expected to apply for full approval of its vaccine. Currently, Moderna's vaccine has received emergency use authorization from the U.S. Food and Drug Administration (FDA).

Pfizer also announced on the 1st that an analysis of Phase 3 trial participants showed the vaccine's prevention effectiveness was 91.3% six months after vaccination. Both Pfizer and Moderna vaccines were developed using the mRNA (messenger ribonucleic acid) method.

This content was produced with the assistance of AI translation services.